Hi Havana19 …. I’m sorry if I have worried you! And I would say a little bit knowledge and familiarity of the scientific lingo goes a long way on HC.
What I am saying is people should be a little bit cautious of the claims being made here. Take for example the NextBiotech news article:
“… the results from its US clinical trial have been provisionally accepted by leading medical journal, Frontiers in Neurology.”
Well you be judge Havana19. What would you call a leading medical journal? Top 20, top 50, top 100?
Go to the legitimate journal ranking site that everyone uses. The SCImago scientific journal rankings.
Search for Frontiers in Neurology. Download the medicine data file into Excel. There are 7436 journals listed. Frontiers in Neurology is ranked at 985. That ranking doesn’t look like one from a “leading medical journal” to me.
So what gives? And how come NTI claim world’s top 10 in their announcement? Well top 10 “open access“ journals. The worlds actual top 10 clinical neurology journals are shown below.
View attachment 1165554
So its all one big “advertorial” - NextBiotech – S3 Corporation – NTI. A lot of vested interests betting the average punter doesn’t understand journal rankings.
Your more substantive question.
As I understand it the Mente device already has FDA approval; neurofeedback device for relaxation.
What NTI seek to do with clinical trials is to create an indication for their device – “neurofeedback device for children with ASD” and a labelling claim “for use by people at home”.
On the plus side this trial seems to have had a credible placebo control. But after that I can only see negatives. When the paper comes out I’ll do a proper critique.
Will this trial be enough to get the indication and labelling claim NTI are seeking?
I am very sceptical. The N’s are too small, the drop-out rate too high and the approach to testing (I am assuming) from the abstract is very weak.
In terms of when to sell your shares?
Well you are in the business of speculative penny stock share trading. The neurofeedback device is like the new fishing lure sold on TV – designed to catch fishers.
So when NextBiotech are telling me to “buy” my first reaction would be to sell.
But it turns out to be more difficult than this because there could well be lots other people who don’t understand journal rankings and maybe I could sell my shares to them at a higher price. In a net sum game this is unfortunately how the business works.
